Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2015 · 10-Q
Revenue$2.75K$2.75K−84.5% vs Q1 2014 Net Income-$480.16K-$480.16KN/M vs Q1 2014 EPS Diluted-$0.01-$0.01N/M vs Q1 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$193,836N/M Margins · derivedGross margin70.0%+17.6 pt vs Q1 2014
Operating margin-15724.3%−12530.9 pt vs Q1 2014
Net margin-17492.0%−13952.9 pt vs Q1 2014
ended Mar 31, 2015 · filed May 19, 2015 · 49 d after period end